280 results on '"Caponigro F"'
Search Results
2. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
3. 862MO Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer
4. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
5. Percorso diagnostico, terapeutico e assistenziale per i tumori di testa e collo – Aggiornamento 2020 AIOCC
6. Phase II study of E7070 in patients with metastatic melanoma
7. Management of recurrent nasopharyngeal carcinoma: current perspectives
8. Therapy of metastatic bladder carcinoma
9. Immunological and Clinical Effects of Thymostimulin in Patients with Locally Advanced Non-Small-Cell Lung Cancer Treated with Combined Chemoradiotherapy
10. A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications
11. Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer
12. Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C
13. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG)
14. Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer
15. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: A phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG)
16. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer
17. A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
18. Translational Research: A Future Strategy for Managing Squamous Cell Carcinoma of the Head and Neck?
19. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer
20. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer
21. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications
22. First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial
23. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications
24. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
25. 1140P - A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
26. OC-005: Afatinib versus methotrexate in recurrent/metastatic HNSCC after platinum therapy: LUX-head and neck
27. LBA47 - First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial
28. PHASE II STUDY OF SECOND LINE VINORELBINE PLUS 5-FU AND FOLINIC ACID (FA) IN ADVANCED COLORECTAL CANCER. PRELIMINARY RESULTS
29. NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC-CANCER - PRELIMINARY-RESULTS OF A PHASE-II TRIAL WITH A MODIFIED FAMTX COMBINATION
30. A phase I-II trial of gefitinib (IRESSA) and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)
31. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer
32. VINORELBINE + 5-FU +ACIDO FOLINICO (AF) NEL TRATTAMENTO DI SECONDA LINEA NEL CARCINOMA DEL COLON-RETTO AVANZATO. DATI PRELIMINARI
33. PREOPERATIVE CHEMOIMMUNOTHERAPY WITH CARBOPLATIN, EPIDOXORUBICIN, 5-FLUOROURACIL AND ALPHA-2B INTERFERON IN LOCALLY ADVANCED INOPERABLE GASTRIC-CANCER
34. Afatinib Versus Methotrexate (Mtx) As Second-Line Treatment for Patients with Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc) Who Progressed After Platinum-Based Therapy: Primary Efficacy Results of Lux-Head & Neck 1, a Phase III Trial
35. Translational Research: A Future Strategy for Managing Squamous Cell Carcinoma of the Head and Neck?
36. EGF-R tyrosyne kinase as new target in melanoma treatment; Synergistic effect of IFN alpha in combination with ZD1839 )Iressa) , an EGFR tyrosine kinase inhibitor
37. Editorial [Hot Topic: ErbB Family and Downstream Signal Transduction Pathways as Targets for Anticancer Therapy (Guest Editor: F. Caponigro)]
38. Phase II study of E7070 in patients with metastatic melanoma.
39. 583 Induction Chemotherapy with Docetaxel, Cisplatin and Capecitabine, Followed by Combined Cetuximab and Radiotherapy in Patients with Locally Advanced Inoperable Head and Neck Cancer. Preliminary Results of a Phase I/II Study
40. Electrochemotherapy, a novel integrated approach to the locoregional treatment of head and neck cancer
41. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.
42. Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer
43. Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer.
44. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
45. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer
46. 715 POSTER Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
47. A phase I study of bortezomib in combination with 5FU/LV plus oxaliplatin in patients (pts) with advanced colorectal cancer (CRC): EORTC 16029
48. Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
49. Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers
50. The ErbB Receptors and their Ligands in Cancer: An Overview
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.